Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
galmedpharma.investorroom.com
Company Research
Source: PR Newswire
TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral SCD1 modulator currently in a Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis provides today a business update and reports financial results for the three and nine months ended September 30, 2019. The Company will host a conference call and webcast at 08:30 ET today.Business DevelopmentDuring the past quarter, the Company announced the initiation of its Phase 3/4 ARMOR, a double-blind, placebo-controlled, global study, to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. The study is designed to consist of two parts. In the first part (Histology-Based) 1200 subjects will be treated with Aramchol or matching placebo for 52 weeks. The Histology-Based data will serve as the basis for the
Show less
Read more
Impact Snapshot
Event Time:
GLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLMD alerts
High impacting Galmed Pharmaceuticals Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GLMD
News
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed publishes Results from Aramchol Phase 3 Open Label part in HepatologyPR Newswire
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesPR Newswire
GLMD
Sec Filings
- 11/14/24 - Form 6-K
- 11/14/24 - Form F-3
- 11/14/24 - Form 6-K
- GLMD's page on the SEC website